We start pre-market with XtalPi Holdings Ltd (2228.HK) trading at HK$10.16 in Hong Kong on 28 Feb 2026. The 2228.HK stock price reflects mixed signals: solid AI drug discovery revenue growth but pressure on margins and cash flow. Recent revenue rose by 52.75% year-over-year while losses narrowed to -1.52 billion CNY in 2024. This snapshot uses exchange data from the HKSE and Meyka AI-powered market analysis platform to set context for short-term and medium-term outlooks.

Pre-market price snapshot and liquidity

The main fact is current 2228.HK stock price HK$10.16 with previous close HK$10.16. Intraday range was HK$10.10 to HK$10.65 on volume 56,017,376.00 shares. Market cap stands at HK$44,582,931,444.00 and average volume is 67,953,829.00, showing healthy trading activity on the HKSE.

AI catalysts and product pipeline

XtalPi sells AI-driven discovery platforms such as XMolGen, XtalFold and Xtalgazer. These tools support small molecules, antibodies, peptides, ADC and PROTAC workflows and drive 2024 revenue growth of 52.75%. Product wins and partnerships in China and international markets remain the primary growth catalyst for 2228.HK stock.

2228.HK stock: Financials and valuation

XtalPi reports EPS HK$1.05 and a trailing PE of 9.87 on the HKSE quote. Key ratios show PB 4.88, price/sales 57.37, and current ratio 9.69, indicating strong liquidity but a premium to sales. Revenue jumped to CNY266.43 million in 2024 while net loss narrowed to -CNY1.52 billion, connecting top-line growth to ongoing R&D and operating costs.

Technical and trading signals for AI stocks traders

Technicals show short-term weakness but potential setup for a rebound in the AI sector. RSI is 29.59 (oversold) and MACD histogram is -0.17, supporting mean-reversion possibilities for 2228.HK stock. Bollinger Bands middle is HK$11.41 and lower band HK$10.20, giving a reference for support and stop levels on HKD-denominated trades.

Meyka AI rates 2228.HK with a score out of 100 and forecast

Meyka AI rates 2228.HK with a score out of 100: 62.90/100 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, industry position, financial growth, key metrics, forecasts, and analyst signals. Meyka AI’s forecast model projects monthly HK$10.44, quarterly HK$13.19, and yearly HK$10.73 for 2228.HK stock. These model outputs are projections and not guarantees.

Risks and opportunities for investors

Primary risks include high price-to-sales, negative free cash flow per share -0.13, and long receivable cycles with days sales outstanding 268.35. Opportunities include accelerating AI adoption in drug discovery, revenue momentum and a strong cash per share 0.92 that cushions short-term spending. Sector trends in Healthcare and AI software will shape 2228.HK stock performance on the HKSE.

Final Thoughts

Key takeaways for 2228.HK stock are straightforward. At HK$10.16, XtalPi combines strong AI-driven revenue growth with stretched valuation metrics versus sales and free cash flow. Meyka AI’s forecast model projects a quarterly target of HK$13.19, implying 29.82% upside versus the current price. The one-year model of HK$10.73 implies 5.61% upside. Meyka AI’s grade of 62.90/100 (B, HOLD) weighs growth, sector position, and financials. Traders should balance the EPS HK$1.05 and trailing PE 9.87 against cash burn and long receivables. Forecasts are model-based projections and not guarantees, and this article is informational, not investment advice. For further company detail see the XtalPi site source and the 2024 financial summary on StockAnalysis source. For a real-time quote use our Meyka stock page at https://meyka.ai/stocks/2228.HK.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.